دورية أكاديمية
Prebiotics for people with cystic fibrosis.
| العنوان: | Prebiotics for people with cystic fibrosis. |
|---|---|
| المؤلفون: | Williams NC; Exercise and Health Research Group, Sport Health and Performance Enhancement (SHAPE) Research Centre, School of Science and Technology., Nottingham Trent University, Nottingham, UK., Jayaratnasingam J; Exercise and Health Research Group, Sport Health and Performance Enhancement (SHAPE) Research Centre, School of Science and Technology., Nottingham Trent University, Nottingham, UK., Prayle AP; Nottingham Cystic Fibrosis and Chidlren's Respiratory Research Centre, University of Nottingham, Nottingham, UK., Nevitt SJ; Department of Health Data Science, University of Liverpool, Liverpool, UK., Smyth AR; Division of Child Health, Obstetrics & Gynaecology (COG), School of Medicine, University of Nottingham, Nottingham, UK. |
| المصدر: | The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2023 Sep 27; Vol. 9. Cochrane AN: CD015236. Date of Electronic Publication: 2023 Sep 27. |
| نوع المنشور: | Systematic Review; Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2004- : Chichester, West Sussex, England : Wiley Original Publication: Oxford, U.K. ; Vista, CA : Update Software, |
| مواضيع طبية MeSH: | Cystic Fibrosis*, Adult ; Child ; Humans ; Feces ; Hospitalization ; Inflammation ; Nutritional Status ; Prebiotics |
| مستخلص: | Background: Cystic fibrosis (CF) is a multisystem disease; the importance of growth and nutritional status is well established given their implications for lung function and overall survivability. Furthermore, it has been established that intestinal microbial imbalance and inflammation are present in people with CF. Oral prebiotics are commercially available substrates that are selectively utilised by host intestinal micro-organisms and may improve both intestinal and overall health. Objectives: To evaluate the benefits and harms of prebiotics for improving health outcomes in children and adults with CF. Search Methods: We searched the Cochrane Cystic Fibrosis Trials Register compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched the reference lists of relevant articles and reviews. Date of last search: 19 October 2022. We also searched PubMed and online trials registries. Date of last search: 13 January 2023. Selection Criteria: Randomised controlled trials (RCTs) and quasi-RCTs assessing the efficacy of prebiotics in children and adults with CF. We planned to only include the first treatment period from cross-over RCTs, regardless of washout period. Data Collection and Analysis: We did not identify any relevant trials. Main Results: We did not identify any relevant trials for inclusion in this review. Authors' Conclusions: This review did not find any evidence for the use of prebiotics in people with CF. Until such evidence is available, it is reasonable for clinicians to follow any local guidelines and to discuss the use of dietary prebiotics with their patients. Large and robust RCTs assessing the dietary prebiotics of inulin or galacto-oligosaccharides or fructo-oligosaccharides, or any combination of these, are needed. Such studies should be of at least 12 months in duration and assess outcomes such as growth and nutrition, gastrointestinal symptoms, pulmonary exacerbations, lung function, inflammatory biomarkers, hospitalisations, intestinal microbial profiling, and faecal short-chain fatty acids. Trials should include both children and adults and aim to be adequately powered to allow for subgroup analysis by age. (Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.) |
| References: | J Pediatr Gastroenterol Nutr. 2015 Apr;60(4):521-6. (PMID: 25539196) N Engl J Med. 1994 Sep 8;331(10):637-42. (PMID: 7503821) Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5934-E5943. (PMID: 27638207) J Bacteriol. 2019 Jul 24;201(16):. (PMID: 31209076) Mediators Inflamm. 2012;2012:948367. (PMID: 22988347) J Hum Nutr Diet. 2022 Jun;35(3):444-454. (PMID: 35092114) PLoS One. 2018 Jun 22;13(6):e0198457. (PMID: 29933382) J Nutr. 1995 Jun;125(6):1401-12. (PMID: 7782892) J Acad Nutr Diet. 2021 Aug;121(8):1574-1590.e3. (PMID: 32532674) Cochrane Database Syst Rev. 2020 Jan 22;1:CD012949. (PMID: 31962375) Br J Nutr. 2005 Apr;93 Suppl 1:S31-4. (PMID: 15877892) Ann Am Thorac Soc. 2015 Nov;12 Suppl 2:S150-6. (PMID: 26595731) Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14. (PMID: 24912386) Clin Nutr. 2014 Aug;33(4):571-80. (PMID: 24767984) Gastroenterol Clin North Am. 2017 Mar;46(1):77-89. (PMID: 28164854) Calcif Tissue Int. 2018 Apr;102(4):443-479. (PMID: 29079996) J Am Diet Assoc. 2008 May;108(5):832-9. (PMID: 18442507) J Cyst Fibros. 2018 Nov;17(6):804-810. (PMID: 29724576) Eur J Clin Nutr. 2018 May;72(5):736-743. (PMID: 29277839) PLoS One. 2018 Dec 6;13(12):e0208171. (PMID: 30521551) Eur J Pediatr. 1999 Jun;158(6):455-9. (PMID: 10378391) Pediatrics. 1964 Jul;34:72-7. (PMID: 14181988) Am J Clin Nutr. 2011 May;93(5):1038-47. (PMID: 21430114) Andrology. 2017 May;5(3):439-444. (PMID: 28245352) Sci Rep. 2016 May 04;6:24857. (PMID: 27143104) Eur J Clin Nutr. 2010 Feb;64(2):146-52. (PMID: 19756029) Patient. 2019 Aug;12(4):419-428. (PMID: 30887269) Lancet Respir Med. 2020 Jan;8(1):65-124. (PMID: 31570318) N Engl J Med. 2011 Nov 3;365(18):1663-72. (PMID: 22047557) Benef Microbes. 2020 Oct 12;11(6):535-545. (PMID: 33032474) Front Pharmacol. 2022 Jun 03;13:877118. (PMID: 35721187) J Clin Epidemiol. 1988;41(6):583-91. (PMID: 3260274) Biol Psychiatry. 2017 Oct 1;82(7):472-487. (PMID: 28242013) Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):605-616. (PMID: 31296969) Int J Epidemiol. 2002 Feb;31(1):140-9. (PMID: 11914310) Clin Transl Immunology. 2016 Apr 22;5(4):e73. (PMID: 27195116) J Pediatr. 2015 Jul;167(1):138-47.e1-3. (PMID: 25818499) J Cyst Fibros. 2022 Sep;21(5):821-829. (PMID: 35086790) mBio. 2012 Aug 21;3(4):. (PMID: 22911969) J Nutr. 2016 Feb;146(2):358-67. (PMID: 26701795) Chest. 2009 Jun;135(6):1610-1618. (PMID: 19447923) BMC Microbiol. 2017 Mar 9;17(1):58. (PMID: 28279152) Lancet. 2010 Mar 20;375(9719):1007-13. (PMID: 20304245) Sci Rep. 2022 Apr 21;12(1):6593. (PMID: 35449374) Appl Environ Microbiol. 2011 Nov;77(22):8015-24. (PMID: 21926193) Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491-502. (PMID: 28611480) Br J Nutr. 2014 Apr 14;111(7):1147-61. (PMID: 24230488) Sci Rep. 2018 Dec 13;8(1):17834. (PMID: 30546102) BMJ Open Respir Res. 2020 Sep;7(1):. (PMID: 32900780) Cochrane Database Syst Rev. 2023 Sep 27;9:CD015236. (PMID: 37753791) Physiol Rev. 2010 Jul;90(3):859-904. (PMID: 20664075) J Clin Endocrinol Metab. 2019 Oct 1;104(10):4427-4440. (PMID: 31188437) J Pediatr. 2017 Feb;181S:S4-S15.e1. (PMID: 28129811) Dig Dis Sci. 2015 Oct;60(10):2946-52. (PMID: 26271615) Clin Nutr. 2016 Jun;35(3):557-77. (PMID: 27068495) N Engl J Med. 2019 Nov 7;381(19):1809-1819. (PMID: 31697873) J Appl Microbiol. 2020 Apr;128(4):934-949. (PMID: 31446668) BMJ. 2011 Jul 22;343:d4002. (PMID: 21784880) Aliment Pharmacol Ther. 2009 Mar 1;29(5):508-18. (PMID: 19053980) BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120) |
| المشرفين على المادة: | 0 (Prebiotics) |
| تواريخ الأحداث: | Date Created: 20230927 Date Completed: 20230928 Latest Revision: 20240928 |
| رمز التحديث: | 20240928 |
| مُعرف محوري في PubMed: | PMC10523429 |
| DOI: | 10.1002/14651858.CD015236.pub2 |
| PMID: | 37753791 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1469-493X |
|---|---|
| DOI: | 10.1002/14651858.CD015236.pub2 |